Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts